Vascular factors and cognition: Toward a prevention of dementia?

Journal of Hypertension, Supplement

Volumn 21, Issue 5, 2003, Pages

  Tzourio, Christophe ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Ageing; Alzheimer's disease; Cognition; Dementia; Hypertension; Prevention; Stroke; Trials

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; INDAPAMIDE; PERINDOPRIL;

BLOOD PRESSURE REGULATION; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; COGNITION; COGNITIVE DEFECT; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMENTIA; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MINI MENTAL STATE EXAMINATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; STROKE; TRANSIENT ISCHEMIC ATTACK;

EID: 0042367603     PISSN: 09521178     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004872-200306005-00004     Document Type: Conference Paper

References (58)

1. Jorm AF, Korten AE, Henderson AS. The prevalence of dementia: a quantitative integration of the literature. Acta Psychiatr Scand 1987; 76:465-479.
2. Ritchie K, Robine JM. La démence sénile en France: une estimation de la charge ponctuelle et projection des tendances futures. Médecine/sciences 1994; 10:680-686.
3. Whitehouse PJ. Dementia. Philadelphia, PA, USA: FA Davis; 1993.
4. Tatemichi TK, Paik M, Bagiella E, Desmond DW, Stern Y, Sano M, et al. Risk of dementia after stroke in a hospitalized cohort: Results of a longitudinal study. Neurology 1994; 44:1885-1891.
5. Zhu L, Fratiglioni L, Guo ZC, Basun H, Corder EH, Winblad B, Viitanen M. Incidence of dementia in relation to stroke and the apolipoprotein E epsilon 4 allele in the very old - Findings from a population-based longitudinal study. Stroke 2000; 31:53-60.
6. Kokmen E, Whisnant JP, O'Fallon WM, Chu CP, Beard CM. Dementia after ischemic stroke: a population-based study in Rochester, Minnesota (1960-1984). Neurology 1996; 46:154-159.
7. Censori B, Manara O, Agostini SC, Camerlingo M, Casto L, Galavotti B, et al. Dementia after first stroke. Stroke 1996; 27:1205-1210.
8. Pohjasvaara T, Erkinjuntti T, Vataja R, Kaste M. Dementia three months after stroke: Baseline frequency and effect of different definitions of dementia in the Helsinki stroke aging memory study (SAM) cohort. Stroke 1997; 28:785-792.
9. Tatemichi TK, Desmond DW, Paik M, et al. Clinical determinants of dementia related to stroke. Ann Neurol 1993; 33:568-575.
10. Tatemichi TK, Desmond DW, Mayeux R, Paik M, Stern Y, Sano Y, et al. Dementia after stroke: baseline frequency, risks, and clinical features in a hospitalized cohort. Neurology 1992; 42:1185-1193.
11. Desmond DW, Moroney JT, Paik MC, Sano M, Mohr JP, Aboumatar S, et al. Frequency and clinical determinants of dementia after ischemic stroke. Neurology 2000; 54:1124-1131.
12. Prencipe M, Ferretti C, Casini AR, Santini M, Giubilei F, Culasso F. Stroke, disability, and dementia: Results of a population survey. Stroke 1997; 28:531-536.
13. Wetterling T, Kanitz RD, Borgis KJ. Comparison of different diagnostic criteria for vascular dementia (ADDTC, DSM-IV, ICD-10, NINDS-AIREN). Stroke 1996; 27:30-36.
14. Drachman D. New criteria for the diagnosis of vascular dementia: Do we know enough yet? Neurology 1993; 43:243-245.
15. Skoog I, Nilsson L, Palmertz B, Andreasson LA, Svanborg A. A population-based study of dementia in 85-years olds. N Engl J Med 1993; 328:153-158.
16. Rocca WA, Hofman A, Brayne C, Breteler MM, Clarke M, Copeland JR, et al. The prevalence of vascular dementia in Europe: Facts and fragments from 1980-1990 studies. Ann Neurol 1991; 30:817-824.
17. Pohjasvaara T, Erkinjuntti T, Ylikoski R, Hietanen M, Vataja R, Kaste M. Clinical determinants of poststroke dementia. Stroke 1998; 29:75-81.
18. Inzitari D, Di Carlo A, Pracucci G, Lamassa M, Vanni P, Romanelli M, et al. Incidence and determinants of poststroke dementia as defined by an informant interview method in a hospital-based stroke registry. Stroke 1998; 29:2087-2093.
19. Wilkie F, Eisendorfer C. Intelligence and blood pressure in the aged. Science 1971; 172:959-962.
20. Kilander L, Nyman H, Boberg M, Hannson L, Lithell H. Hypertension is related to cognitive impairment. A 20-year follow-up of 999 men. Hypertension 1998; 31:780-786.
21. Launer LJ, Masaki K, Petrovitch H, Foley D, Havlik RJ. The association between midlife blood pressure levels and late-life cognitive function. The Honolulu-Asia aging study. JAMA 1995; 274:1846-1851.
22. Peila R, White LR, Petrovich H, Masaki K, Ross GW, Havlik RJ, Launer LJ. Joint effect of the APOE gene and midlife systolic blood pressure on late-life cognitive impairment - The Honolulu-Asia aging study. Stroke 2001; 32:2882-2887.
23. Swan GE, Decarli C, Miller BL, Reed T, Wolf PA, Jack LM, Carmelli D. Association of midlife blood pressure to late-life cognitive decline and brain morphology. Neurology 1998; 51:986-993.
24. Kivipelto M, Helkala EL, Laakso MP, Hanninen T, Hallikainen M, Alhainen K, et al. Midlife vascular risk factors and Alzheimer's disease in later life: longitudinal, population based study. BMJ 2001; 322(7300):1447-1451.
25. Farmer ME, Kittner SJ, Abbott RD, Wolz MM, Wolf PA, White LR. Longitudinally measured blood pressure, antihypertensive medication use, and cognitive performance: the Framingham Study. J Clin Epidemiol 1990; 43:475-480.
26. Scherr PA, Hebert LE, Smith LA, Evans DA. Relation of blood pressure to cognitive function in the elderly. Am J Epidemiol 1991; 134:1303-1315.
27. Zhu L, Viitanen M, Guo ZC, Winblad B, Fratiglioni L. Blood pressure reduction, cardiovascular diseases, and cognitive decline in the mini-mental state examination in a community population of normal very old people: A three-year follow-up. J Clin Epidemiol 1998; 51:385-391.
28. van Boxtel MPJ, Gaillard C, Houx PJ, Buntinx F, de Leeuw PW, Jolles J. Can the blood pressure predict cognitive task performance in a healthy population sample? J Hypertens 1997; 15:1069-1076.
29. Morris MC, Scherr PA, Hebert LE, Glynn RJ, Bennett DA, Evans DA. Association of incident Alzheimer disease and blood pressure measured from 13 years before to 2 years after diagnosis in a large community study. Arch Neurol 2001; 58:1640-1646.
30. Skoog I, Lernfelt B, Landahl S, Palmertz B, Andreasson LA, Nilsson L, et al. 15-year longitudinal study of blood pressure and dementia. Lancet 1996; 347:1141-1145.
31. Guo ZC, Fratiglioni L, Zhu L, Fastbom J, Winbald B, Viitanen M. Occurrence and progression of dementia in a community population aged 75 years and older - Relationship of antihypertensive medication use. Arch Neurol 1999; 56:991-996.
32. Veld BAI, Ruitenberg A, Hofman A, Stricker BHC, Breteler MM. Antihypertensive drugs and incidence of dementia: the Rotterdam Study. Neurobiol Aging 2001; 22:407-412.
33. Dufouil C, Ducimetière P, Alpérovitch A. Sex differences for association between alcohol consumption and cognitive performance. Am J Epidemiol 1997; 146:405-412.
34. Orgogozo JM, Dartigues JF, Lafon S. Wine consumption and dementia in the elderly: a prospective community study in the Bordeaux area. Rev Neurol 1997; 153:185-192.
35. Ruitenberg A, van Swieten JC, Witteman JCM, Mehta KM, van Duijn CM, Hofman A, Breteler M. Alcohol consumption and risk of dementia: the Rotterdam Study. Lancet 2002; 359:281-286.
36. Ott A, Stolk RP, vanHarskamp F, Pols HA, Hofman A, Breteler MM. Diabetes mellitus and the risk of dementia - The Rotterdam Study. Neurology 1999; 53:1937-1942.
37. Luchsinger JA, Tang MX, Stern Y, Shea S, Mayeux R. Diabetes mellitus and risk of Alzheimer's disease and dementia with stroke in a multiethnic cohort. Am J Epidemiol 2001; 154:635-641.
38. Seshadri S, Beiser A, Selhub J, Jacques PF, Rosenberg IH, D'Agostino RB, et al. Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N Engl J Med 2002; 346:476-483.
39. intVeld BA, Ruitenberg A, Hofman A, Launer MJ, van Duijn CM, Stijnen T, et al. Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease. N Engl J Med 2001; 345:1515-1521.
40. Jick H, Zornberg GL, Jick SS, Seshadri S, Drachman DA. Statins and the risk of dementia. Lancet 2000; 356:1627-1631.
41. Rockwood K, Kirkland S, Hogan DB, MacKnight C, Merry H, Verrault R, et al. Use of lipid-lowering agents, indication bias, and the risk of dementia in community-dwelling elderly people. Arch Neurol 2002; 59:223-227.
42. Longstreth WT, Manolio TA, Arnold A, Burke GL, Bryan N, Jungreis CA, et al. Clinical correlates of white matter findings on cranial magnetic resonance imaging of 3301 elderly people: The cardiovascular health study. Stroke 1996; 27:1274-1282.
43. Breteler MM, van Swieten JC, Bots ML, Grobbee DE, Claus JJ, van den Hour JH, et al. Cerebral white matter lesions, vascular risk factors and cognitive function in a population-based study: the Rotterdam study. Neurology 1994; 44:1246-1252.
44. Liao DP, Cooper L, Cai JW, Toole JF, Bryan NR, Hutchinson RG, Tyroler HA. Presence and severity of cerebral white matter lesions and hypertension, its treatment, and its control: The ARIC study. Stroke 1996; 27:2262-2270.
45. Manolio TA, Kronmal RA, Burke GL, Poirier V, O'Leary DH, Gardin JM, et al. Magnetic resonance abnormalities and cardiovascular disease in older adults. The Cardiovascular Health Study. Stroke 1994; 25:318-327.
46. van Swieten JC, Geyskes GG, Derix MMA. Hypertension in the elderly is associated with white matter lesions and cognitive decline. Ann Neurol 1991; 30:825-830.
47. Roman GC. From UBOs to Binswanger's disease: Impact of magnetic resonance imaging on vascular dementia research. Stroke 1996; 27:1269-1273.
48. Pantoni L, Garcia JH. Pathogenesis of leukoaraiosis: A review. Stroke 1997; 28:652-659.
49. Junqué C, Pujol J, Vendrell P, Bruna O, Kodar M, Ribas JC, et al. Leukoaraiosis on magnetic resonance imaging and speed of mental processing. Arch Neurol 1990; 47:151-156.
50. Almkvist O, Wahlund LO, Andersson-Lundman G, Basun H, Backman L. White-matter hyperintensity and neuropsychological functions in dementia and healthy aging. Arch Neurol 1992; 49:626-632.
51. Mirsen TR, Lee DH, Wong CJ, Diaz JF, Fox AJ, Hachinski VC, Merskey H. Clinical correlates of white-matter changes on magnetic resonance imaging scans of the brain. Arch Neurol 1991; 48:1015-1021.
52. Rao SM, Mittenberg W, Bernardin L, Haughton VM, Leo GJ. Neuropsychological test findings in subjects with leukoaraiosis. Arch Neurol 1989; 46:40-44.
53. Prince MJ, Bird AS, Blizard RA, Mann AH. Is the cognitive function of older patients affected by antihypertensive treatment? Results from 54 months of the Medical Research Council's trial of hypertension in older adults. BMJ 1996; 312:801-805.
54. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991; 265:3255-3264.
55. Forette F, Seux ML, Staessen JA, Thijs L, Birkenhager WH, Babarskiene MR, et al. Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial. Lancet 1998; 352:1347-1351.
56. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358:1033-1041.
57. The PROGRESS Collaborative Group. Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Arch Intern Med 2003; 163:1069-1075.
58. Brookmeyer R, Gray S, Kawas C. Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset. Am J Public Health 1998; 88:1337-1342.